Sarepta therapeutics announces topline results from embark, a global pivotal study of elevidys gene therapy for duchenne muscular dystrophy

Cambridge, mass.--(business wire)--sarepta therapeutics announces the topline results from embark, a global pivotal study of elevidys gene therapy for duchenne muscular dystrophy.

SRPT Ratings Summary

SRPT Quant Ranking